Uterine Serous Carcinoma Recruiting Phase 2 Trials for Niraparib (DB11793)

IndicationStatusPhase
DBCOND0122528 (Uterine Serous Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04080284Trial of Maintenance With Niraparib- Uterine Serous CarcinomaTreatment